跳转至内容
Merck
CN

06563

甲氨蝶呤 水合物

≥99.0% (sum of enantiomers, HPLC)

别名:

对-[(2,4-二氨基喋啶-6)-N-甲基甲氨基]苯甲酰谷氨酸 水合物, L-氨甲喋呤 水合物, MTX 水合物, 氟安定 水合物, 氨甲叶酸 水合物, 氨甲喋呤 水合物

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C20H22N8O5 · xH2O
化学文摘社编号:
133073-73-1
分子量:
454.44 (anhydrous basis)
PubChem Substance ID:
329748247
UNSPSC Code:
12352202
NACRES:
NA.77
EC Number:
200-413-8
MDL number:
MFCD00150847

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

FPJYMUQSRFJSEW-ZOWNYOTGSA-N

InChI

1S/C20H22N8O5.H2O/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);1H2/t13-;/m0./s1

biological source

synthetic

assay

≥99.0% (sum of enantiomers, HPLC)

form

powder or crystals

optical activity

[α]/D +21.0±2.0°

impurities

≤0.1% sulfated ash

mp

185-204 °C

solubility

water: insoluble

storage temp.

−20°C

Quality Level

200

Gene Information

human ... DHFR(1719)

正在寻找类似产品? 访问 产品对比指南

General description

甲氨蝶呤是叶酸的类似物。它通过多种细胞机制展示出抗炎作用。抑制二氢叶酸还原酶可以减少嘧啶和嘌呤的从头合成、磷脂和蛋白质的转甲基作用以及聚胺的形成。

Application

二氢叶酸还原酶的有效抑制剂 和抗肿瘤的研究试剂。 用于抑制二氢叶酸还原酶在DHFR蛋白表达系统中的表达。
二氢叶酸还原酶的有效抑制剂 和抗肿瘤的研究试剂。 用于抑制二氢叶酸还原酶在DHFR蛋白表达系统中的表达。也显示免疫抑制作用，如类风湿关节炎。
二氢叶酸还原酶的有效抑制剂 和抗肿瘤的研究试剂。 用于抑制二氢叶酸还原酶在DHFR蛋白表达系统中的表达。还可有效治疗耐甲氧嘧啶的 间日 疟原虫。
甲氨蝶呤水合物可用作改善病情抗风湿药（DMARD），用于研究其对小鼠模型中罗斯河病毒疾病（RRVD）的作用。

Other Notes

叶酸拮抗剂。二氢叶酸还原酶的有效抑制剂。

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1

target_organs

Liver,Bone marrow

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCCK6153
BCCG7967
BCCB8864
BCBV8405
BCBN2516V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Methotrexate Treatment Causes Early Onset of Disease in a Mouse Model of Ross River Virus-Induced Inflammatory Disease through Increased Monocyte Production
Adam Taylor, et al.
PLoS ONE (2013)
D A Matthews et al.
Science (New York, N.Y.), 197(4302), 452-455 (1977-07-29)
A central eight-stranded beta-pleated sheet is the main feature of the polypeptide backbone folding in dihydrofolate reductase. The innermost four strands and two bridging helices are geometrically similar to but are connected in a different way from those in the
B N Cronstein
Rheumatic diseases clinics of North America, 23(4), 739-755 (1997-11-15)
Because of methotrexate's well-documented efficacy in the treatment of rheumatoid arthritis, it is important that we understand the mechanism of action of this drug. There are two biochemical mechanisms by which methotrexate may modulate inflammation: (1) promotion of adenosine release
Edwin S L Chan et al.
Nature reviews. Rheumatology, 6(3), 175-178 (2010-03-04)
Methotrexate remains a cornerstone in the treatment of rheumatoid arthritis and other rheumatic diseases. Folate antagonism is known to contribute to the antiproliferative effects that are important in the action of methotrexate against malignant diseases, but concomitant administration of folic
Josef Singer et al.
Molecular cancer therapeutics, 13(7), 1777-1790 (2014-04-24)
Passive immunotherapy with monoclonal antibodies represents a cornerstone of human anticancer therapies, but has not been established in veterinary medicine yet. As the tumor-associated antigen EGFR (ErbB-1) is highly conserved between humans and dogs, and considering the effectiveness of the
查看所有相关文献

相关内容

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持